Indomethacin () antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-205-Ag01	BSA-Indomethacin	756
GMP-SMT-205-Ag02	OVA-Indomethacin	756
GMP-SMT-205-Ab01	Anti-Indomethacin mouse monoclonal antibody (mAb)	1953
GMP-SMT-205-Ab02	Anti-Indomethacin human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-205-Ag01
Product Name	BSA-Indomethacin
Target/Biomarker	Indomethacin(NULL)
Expression platform	Synthetic
Bioactivity validation	Indomethacin (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Indomethacin (NULL) / OVA-Indomethacin (NULL) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-205-Ag02
Product Name	OVA-Indomethacin
Target/Biomarker	Indomethacin(NULL)
Expression platform	Synthetic
Bioactivity validation	Indomethacin (NULL) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Indomethacin (NULL) / OVA-Indomethacin (NULL) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-205-Ab01
Product Name	Anti-Indomethacin mouse monoclonal antibody (mAb)
Target/Biomarker	Indomethacin(NULL)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human Indomethacin (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Indomethacin (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Indomethacin (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-205-Ab02
Product Name	Anti-Indomethacin human monoclonal antibody (mAb)
Target/Biomarker	Indomethacin(NULL)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Human Indomethacin (NULL) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Indomethacin (NULL) antibodies in NULL level test of Inflammation/autoimmune/inflammatory disease (NULL) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human Indomethacin (NULL) monoclonal antibody (mAb) is a monoclonal antibody produced by hybridoma technology.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. What is Indomethacin, and what is its role in in vitro diagnosis (IVD)? Indomethacin is a potent nonsteroidal anti-inflammatory drug (NSAID) belonging to the indole-acetic acid derivative class. It is widely recognized for its therapeutic properties, particularly in the management of pain, inflammation, and fever. While Indomethacin itself is not a target molecule for in vitro diagnosis (IVD), its utilization is integral to various medical conditions, making IVD assessments an essential component of patient care. Role in IVD: Indomethacin plays a crucial role in the context of IVD, primarily as a therapeutic agent for a range of medical conditions. IVD, or in vitro diagnostics, encompass a multitude of laboratory tests and assays that are performed on samples such as blood, urine, or tissue to provide valuable insights into a patient's health status and disease management. While Indomethacin is not directly measured through these diagnostics, its prescription and use are intrinsically linked to IVD in the following ways: 1. Monitoring Treatment Efficacy: Indomethacin is frequently prescribed to individuals suffering from conditions characterized by inflammation, such as rheumatoid arthritis or gout. IVD tests are instrumental in monitoring the effectiveness of Indomethacin therapy. They assess biomarkers, pain indices, and inflammation markers to gauge how well the drug is alleviating discomfort and reducing inflammation. This allows healthcare providers to make informed decisions regarding treatment adjustments or alternative therapies. 2. Assessing Disease Progression: For chronic conditions that necessitate long-term Indomethacin treatment, IVD diagnostics serve as essential tools for assessing disease progression. By tracking relevant biomarkers, these tests help healthcare practitioners understand how the patient's condition is evolving. This information is critical for determining the appropriate course of treatment and whether modifications are required to achieve better outcomes. 3. Detecting Adverse Effects: While Indomethacin offers valuable therapeutic benefits, it is not without potential side effects. IVD plays a pivotal role in identifying adverse reactions or alterations in physiological parameters associated with Indomethacin usage. Regular monitoring ensures early detection of any issues, enabling healthcare providers to address them promptly. This proactive approach contributes to patient safety and well-being. 2. Why Measure Indomethacin? It is essential to clarify that direct measurement of Indomethacin via IVD is not a standard practice in clinical settings. Instead, IVD assessments prioritize the evaluation of its effects on specific disease-related parameters and biomarkers. The rationale for monitoring these indirect indicators is multifaceted: 1. Treatment Efficacy Assessment: Healthcare providers rely on IVD tests to evaluate the efficacy of Indomethacin in managing the underlying condition. By tracking disease-specific markers and symptoms, practitioners can determine whether the drug is effectively reducing inflammation, alleviating pain, and improving the patient's overall well-being. Positive changes in these markers indicate successful treatment outcomes. 2. Safety Profiling: While Indomethacin is an effective medication, it can potentially lead to adverse effects or complications in some individuals. Regular IVD assessments contribute to safety profiling by identifying any deviations in physiological parameters or biomarkers that may signal an adverse reaction. Detecting such issues early allows healthcare providers to take necessary actions, such as adjusting the dosage or considering alternative treatments, to ensure patient safety and minimize risks. 3. Disease Progression Monitoring: For chronic conditions like rheumatoid arthritis, where Indomethacin is a long-term therapeutic option, monitoring disease progression markers is vital. IVD tests provide insights into how the disease is evolving, helping healthcare professionals make informed decisions about treatment plans. They can determine whether adjustments are needed to manage the condition effectively and prevent further joint damage or complications. In conclusion, while IVD does not involve the direct quantification of Indomethacin levels, its significance lies in its essential role in the management of inflammatory and pain-related disorders. IVD assessments indirectly measure the impact of Indomethacin by evaluating disease-specific parameters, safety profiles, and treatment efficacy. This comprehensive approach empowers healthcare providers to optimize patient outcomes and ensure the well-being of individuals receiving Indomethacin therapy.

About GDU